Connect with us

Health

Halifax lab team to conduct first Canadian trials for possible COVID-19 vaccine – ThoroldNews.com

Published

 on


HALIFAX — The first Canadian clinical trials for a possible COVID-19 vaccine will be conducted by a Halifax research team that also was involved in trials that eventually led to a vaccine for the Ebola virus.

Health Canada has approved trials that will be conducted at the Canadian Centre for Vaccinology at Dalhousie University.

The centre’s director, Dr. Scott Halperin, says the lab was one of several in Canada and the U.S. whose work starting in 2014 eventually saw an “emergency release” of an Ebola vaccine that was used in West Africa before a third phase of clinical trials had been completed.

Halperin said each lab did slightly different studies in order to get the right type of information before quickly moving to the second phase and then the third.

“The Phase 1 studies were done and within six months the data were available and the phase three studies were started in West Africa which then helped to actually stop the epidemic,” he said in an interview.

Halperin said it’s possible the same emergency release could happen in Canada with a potential COVID-19 vaccine if it shows potential and is deemed safe, expediting a process that usually takes a number of years to complete — anywhere from five to seven years under normal circumstances.

“That would be something that Health Canada and the Canadian government would have to decide whether they wanted to do that. But it is certainly one of the options in the tool kit of things they can do to expedite the process if this or any other vaccine is looking promising.”

Halperin pointed out that despite its early use during testing, the Ebola vaccine wasn’t actually licensed as a regular marketed vaccine until late last year.

However, he cautions there’s much work to be done before a COVID-19 vaccine could be approved for use.

The Halifax researchers will be following up work by Chinese manufacturer CanSino Biologics, which is already conducting human clinical trials for the vaccine.

Halperin said the first phase trial should be underway within the next three weeks once final approval is given by the centre’s research ethics board.

Phase 1 will involve fewer than 100 healthy volunteers between the ages of 18 and 55 who will be followed over the next six months.

“We want to make sure that the vaccine is safe first in younger individuals before we go into people who may be at higher risk,” Halperin said.

The participants are given a dose of the vaccine and are clinically monitored through a series of blood tests. They are also asked to record their symptoms in a diary so the researchers can have even more information.

“We collect any type of symptoms they might have whether they think it’s related to the vaccine or not,” said Halperin.

Each participant will make between nine and 13 visits to the centre during the first phase of the study.

If the initial test group shows a safe immune response to the vaccine, Halperin said researchers will quickly transition into an expanded second phase study before the first phase is even completed.

That would involve hundreds of people of all ages, including those aged 65 to 85, and would be administered by several other research centres across the country that are part of the Canadian Immunization Research Network.

Halperin said the network was set up by the federal government in 2009 as part of the response to the H1N1 pandemic. He said the intent was to create the necessary infrastructure to respond rapidly to an emergency and to do early phase clinical trials so vaccines would be available in Canada.

“This is a good test of that (network),” Halperin said of clinical trials that will be the first of “many more to come.”

This report by The Canadian Press was first published May 17, 2020.

Keith Doucette, The Canadian Press

Let’s block ads! (Why?)



Source link

Continue Reading

Health

Monkeypox: Cases found and suspected in Portugal, Spain – CTV News

Published

 on


LISBON –

Portuguese authorities said on Wednesday they had identified five cases of rare monkeypox infection and Spain’s health services are testing eight potential cases after Britain put Europe on alert for the virus.

The five Portuguese patients, out of 20 suspected cases, are all stable. They are all men and they all live in the region of Lisbon and the Tagus Valley, the Portuguese health authorities said.

European Health authorities are monitoring any outbreak of the disease since Britain has reported its first case of monkeypox on May 7 and found six more in the country since then. 

None of the eight suspected cases in Spain has been confirmed yet, the Spanish Health Ministry said in a statement on Wednesday.

Monkeypox is a rare viral infection similar to human smallpox, though milder, first recorded in the Democratic Republic of Congo in the 1970s. The number of cases in West Africa has increased in the last decade.

Symptoms include fever, headaches and skin rashes starting on the face and spreading to the rest of the body.

It is not particularly infectious between people, Spanish health authorities said, and most people infected recover within a few weeks, though severe cases have been reported.

Four of the cases detected in Britain self-identified as gay, bi-sexual or other men who have sex with men, the U.K. Health Security Agency said, adding evidence suggested there may be a transmission in the community.

The agency in Britain urged men who are gay and bisexual to be aware of any unusual rashes or lesions and to contact a sexual health service without delay.

The Spanish Health Ministry and Portugal’s DGS health authority Spanish did not release any information on the sexual orientation of the monkeypox patients or suspected patients.

The two countries sent out alerts to health professionals in order to identify more possible cases.

(Reporting by Patricia Rua in Lisbon and Christina Thykjaer in Madrid; Editing by Inti Landauro and Alison Williams)

Adblock test (Why?)



Source link

Continue Reading

Health

Long Covid Patients' Symptoms Helped After Vaccination in Study – BNN

Published

 on


(Bloomberg) — Fewer Covid-19 patients reported lingering symptoms from the infection after getting vaccinated, according to a study that suggests the shots could help alleviate the burden of long Covid. 

A first vaccine dose after infection with the virus was associated with a 13% decline in the odds of having long Covid and a second shot with a 9% drop in the study published Thursday in the BMJ. Over the course of seven months in 2021, researchers regularly visited the households of more than 28,000 people to ask whether they were experiencing symptoms long after infection.

The findings, together with evidence that long Covid is reduced in those infected after vaccination, suggest that jabs may help decrease the prevalence of persisting symptoms.

“The large scale of this study means that we can be fairly confident about what has been observed, but it does not mean we can be sure what it means,” said Peter English, a former chair of the BMA Public Health Medicine Committee. 

“The most obvious — and perhaps the most likely inference — is that vaccination does prevent at least some cases of long Covid, and may reduce the severity of symptoms,” he said in emailed comments. But “we cannot yet say this with any confidence.” English wasn’t involved in the research. 

An estimated 1.8 million people in the UK had reported experiencing long Covid as of April 2022, with two in three people saying the symptoms had affected their day-to-day activities, according to the latest Office for National Statistics data.

The scientists who ran the study called for more research to “understand the biological mechanisms underpinning any improvements in symptoms after vaccination, which may contribute to the development of therapeutics for long Covid.” 

©2022 Bloomberg L.P.

Adblock test (Why?)



Source link

Continue Reading

Health

Europe, US on alert after new monkeypox cases emerge – Al Jazeera English

Published

 on


US, Spain and Portugal announce cases of rare viral infection, two weeks after UK identified its first case.

Health authorities are on alert for the spread of monkeypox, a rare viral disease first reported in the Democratic Republic of Congo in the 1970s, after new cases emerged in Europe, and the United States confirmed its first infection.

Portugal said on Wednesday it had identified five cases of monkeypox, Spain said it was testing 23 potential cases, and the US state of Massachusetts announced it had found a case in a man who recently travelled to Canada.

The United Kingdom was the first to confirm a case of monkeypox earlier this month. It has now detected seven cases and is working with the World Health Organization (WHO) to investigate the virus’s spread after being unable to make a link between the initial case, in a man who had travelled from Nigeria, and the more recent ones.

Health authorities suspect some of the infections may have occurred through sexual contact – in this instance among gay or bisexual men – with four of the UK cases identified among people who visited sexual health clinics after developing the rash associated with monkeypox.

“No source of infection has yet been confirmed for either the family or GBMSM clusters,” the WHO said in a statement in Wednesday. “Based on currently available information, infection seems to have been locally acquired in the United Kingdom. The extent of local transmission is unclear at this stage and there is the possibility of identification of further cases.”

Monkeypox, which is similar to human smallpox, typically begins with a flu-like illness and swelling of the lymph nodes, followed by a rash on the face and body. Most people recover from the illness, which is endemic in parts of central and western Africa and usually the result of close contact with infected animals, within a few weeks, but it can be fatal.

The five Portuguese patients, out of 20 suspected cases, are all in a stable condition, according to the country’s health authorities. They are all men who live in the region of Lisbon and the Tagus Valley, they added.

Health authorities in Madrid said the cases discovered in Spain appeared to be linked to sexual contact.

“In general, its transmission is via respiratory drops but the characteristics of the 23 suspected infections point to it being passed on through bodily fluids during sex relations,” they said in a statement, without giving further details.

“All of them are young adult males and most of them are men who have sexual relations with other men, but not all of them,” Elena Andradas, head of public health in the Madrid region, told Cadena Ser radio.

US health officials said the Massachusetts man who developed monkeypox went to Canada to see friends at the end of April and returned home in early May. He is currently being treated in hospital.

Jennifer McQuiston from the US Centers for Disease Control and Prevention (CDC) said while it was the only case the CDC was aware of, “I do think we are preparing for the possibility of more cases”.

The agency is in contact with its counterparts in the UK and Canada as part of the investigation, but McQuiston said no link had been established so far.

There are two types of monkeypox virus: the West African clade and Congo Basin (Central African) clade. The case-fatality ratio for the West African clade has been documented to be about 1 percent, and up to 10 percent for patients with the Congo Basin clade.

The WHO said that while smallpox vaccination has been effective against monkeypox, the end of mass vaccination programmes for smallpox meant people under the age of 40 or 50 no longer had that protection.

The UK has previously reported cases of monkeypox – all linked to travel to Nigeria – as has the US. An outbreak there in 2003 was traced to pet prairie dogs that had been housed with small animals imported from Ghana that were found to have the virus.

Adblock test (Why?)



Source link

Continue Reading

Trending